Iqirvo in Nepal

Iqirvo - overview

Iqirvo (resmetirom) is manufactured by Madrigal Pharmaceuticals and indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. It is an oral PPARα/δ dual agonist, 80 mg once daily approved by the US FDA in 2024 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.

Access in Nepal

Nepal's DDA has a personal-use pathway; volumes are small but process exists.

How Reserve Meds coordinates access in Nepal

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Nepal-specific eligibility.
3. Treating physician in Nepal issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Iqirvo from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.

Typical timeline for Nepal

End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Nepal ask

• Is the pathway legal in Nepal? Yes - it operates under Nepal's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Nepal able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Iqirvo in Nepal

Join the Iqirvo waitlist